The Psychedelics Lobby: Tracking Federal Lobbying by Psychedelics Companies and Nonprofits Post published:September 30, 2024 Post category:Analysis/News/Pα+
Real-World Data Reveals Variability in Access to, and Use of, Spravato Post published:September 13, 2024 Post category:Analysis/News/Pα+
What Does FDA Expect from Lykos’ Next Phase 3 MDMA Study? (Part 2) Post published:August 28, 2024 Post category:Analysis/News/Pα+
What Does FDA Expect from Lykos’ Next Phase 3 MDMA Study? (Part 1) Post published:August 22, 2024 Post category:Analysis/News/Pα+
Breaking: Lykos Lays Off 75% of Staff, Ropes In Pharma Veteran, Doblin Resigns Board Post published:August 15, 2024 Post category:Analysis/News/Pα+
Lykos Plots FDA Appeal: Reeling from CRL and Journal Article Retractions, MDMA Developer Hopes to Change Your Mind Post published:August 13, 2024 Post category:Analysis/News/Pα+
BREAKING: FDA Rejects Lykos Therapeutics’ MDMA-Assisted Therapy For PTSD Post published:August 9, 2024 Post category:Analysis/News
Vibe Check: FDA Set to Decide Future of MDMA-Assisted Therapy This Week Post published:August 6, 2024 Post category:Analysis/News